Objective-Plant-derived ␣-linolenic acid (ALA) may constitute an attractive cardioprotective alternative to fish-derived n-3 fatty acids. However, the effect of dietary ALA on arterial thrombus formation remains unknown. Methods and Results-Male C57Bl/6 mice were fed a high-ALA or low-ALA diet for 2 weeks. Arterial thrombus formation was delayed in mice fed a high-ALA diet compared with those on a low-ALA diet (nϭ7; PϽ0.005). Dietary ALA impaired platelet aggregation to collagen and thrombin (nϭ5; PϽ0.005) and decreased p38 mitogen-activated protein kinase activation in platelets. Dietary ALA impaired arterial tissue factor (TF) expression, TF activity, and nuclear factor-B activity (nϭ7; PϽ0.05); plasma clotting times and plasma thrombin generation did not differ (nϭ5; Pϭnot significant). In cultured human vascular smooth muscle and endothelial cells, ALA inhibited TF expression and activity (nϭ4; PϽ0.01). Inhibition of TF expression occurred at the transcriptional level via the mitogen-activated protein kinase p38 in smooth muscle cells and p38, extracellular signal-regulated kinases 1 and 2, and c-Jun N-terminal kinases 1 and 2 in endothelial cells. 
A rterial thrombosis is the critical step in the development of acute vascular syndromes. [1] [2] [3] Circulating platelets are activated by interaction with subendothelial collagen at the site of an injury. 4 In parallel, membrane-bound tissue factor (TF) expressed on vascular cells acts as a receptor for activated factor VII (VIIa). 5, 6 The TF/VIIa complex triggers the coagulation cascade and the formation of activated factor X (Xa), ultimately resulting in thrombin formation, which in turn cleaves protease-activated receptors on the platelet surface, boosting platelet activation and clot formation. 4 The critical role of platelets and TF in the pathogenesis of acute coronary syndromes has indeed been well documented. [7] [8] [9] Experimental and epidemiological studies have extensively characterized the cardioprotective and antithrombotic effects of fish-derived dietary long-chain n-3 fatty acids (FAs) eicosapentaenoic acid (EPA) (C20:5 n-3) and docosahexaenoic acid (DHA) (C22:6 n-3). 10 -13 Consistent with these observations, an increased risk for developing cardiovascular disease was identified in populations with low intake of EPA and DHA, prompting the American Heart Association to modify its nutrition guidelines. 14 ␣-Linolenic acid (ALA) is an essential n-3 FA found at high concentrations in vegetable oils, in particular flaxseed oil, where it accounts for 50% of the total FA content. Following oral intake, ALA is partially converted into EPA and DHA. The rate of conversion of ALA into long-chain n-3 FAs ranges from 0.05% to 10%. 15 In recent epidemiological studies, ALA consumption has been inversely associated with the incidence of myocardial infarction, sudden cardiac death, and coronary artery calcification. 16 -20 Despite these promising data, the precise biological mechanisms mediating the cardioprotective effects of ALA remain barely understood. In particular, it remains controversial whether the rather poor conversion of ALA to EPA and DHA can account for the beneficial effects of ALA or whether ALA exerts direct biological effects. 21, 22 Because increasing evidence suggests that ALA can serve as a cardioprotective nutritional supplement, this study addresses the question whether dietary ALA inhibits thrombus formation in vivo and analyzes the mechanisms involved.
Materials and Methods
For details, please see the Supplemental Materials and Methods, available online at http://atvb.ahajournals.org.
ALA Diet and Carotid Artery Thrombosis Model
C57BL/6 mice were fed a 0.21% (w/w) cholesterol diet containing either a high (7.3%) or low (0.03%) ALA concentration (Supplemental Table I) . 23 Photochemical injury model was performed after 2 weeks of treatment.
Immunohistochemistry
Thrombus composition was analyzed in paraffin-fixed sections from occluded carotid arteries. Sections were stained for TF, fibrin, and the platelet marker CD41.
Prothrombin Time and Activated Partial Thromboplastin Time
Plasma was isolated from citrated blood (3.2%; 1/10) by centrifugation (2500g; 4°C; 15 minutes). Prothrombin time and activated partial thromboplastin time were assessed using the START 4 analyzer (Diagnostica Stago). 24 
Thrombin Generation
Plasma thrombin generation was monitored by automated calibrated thrombography and the results analyzed using Thrombinoscope software (Thrombinoscope BV, Maastricht, the Netherlands). 25, 26 
Platelet Aggregation
Platelet aggregation was studied by whole blood impedance aggregometry (Chrono-Log, Havertown, PA).
FA Profile in Aortic Tissue
FA profiles of the pooled tissues were analyzed by gas chromatography as described. 27 Measurements were performed in duplicate, and the mean value is displayed.
Cell Culture
Human aortic vascular smooth muscle cells (VSMC) (Clonetics, Allschwil, Switzerland) and human aortic endothelial cells (HAEC) (Clonetics) were cultured as described. 24 Protein expression was determined by Western blot analysis and RNA by real-time polymerase chain reaction.
TF Activity
Factor Xa generation on the surface of VSMC or HAEC or in tissues was analyzed using a colorimetric assay (Actichrome, American Diagnostica Inc).
TF Promoter Activity
TF promoter activity was measured as described. 28 A minimal TF promoter (Ϫ227 bp to ϩ121 bp) was cloned upstream of the firefly luciferase reporter gene, and a recombinant adenoviral vector was constructed. HAEC were transduced with the vector Ad5/hTF/Luc (100 pfu/cell) for 1 hour. An adenoviral vector without reporter gene (VQAd/Empty) was used as a negative control. After transduction, HAEC were grown in medium (10% fetal bovine serum) for 24 hours and then serum-starved for 24 hours before tumor necrosis factor-␣ (TNF-␣) stimulation with or without ALA (30 mol/L) pretreatment. Firefly luciferase activity was determined by luminometer (Berthold Technologies, Bad Wildbad, Germany) and normalized to the protein concentration in the lysates.
Nuclear Extracts and Nuclear Factor-B Activity
Nuclear extracts were obtained from HAEC or mouse aorta using a nuclear extraction kit (Active Motif), and nuclear factor-B (NF-B) activity was measured using a TransAM NF-B p65 kit (Active Motif).
Statistics
Data are presented as meanϮSEM. Statistics were performed using GraphPad Prism 4.0 software (GraphPad Software Inc, La Jolla, CA). Statistical analysis was performed using a 2-tailed unpaired Student t test or 1-way ANOVA as appropriate. A value of PϽ0.05 was considered significant.
Results

Dietary ALA Inhibits Arterial Thrombosis
C57BL/6 mice were fed for 2 weeks a 0.21% cholesterol diet containing either 7.3% (w/w) ALA (high ALA, treated group) or 0.03% (w/w) ALA (low ALA, control group). No difference in body weight was observed after 2 weeks of diet (nϭ7; Pϭnot significant [NS]; data not shown). Aorta from animals fed a high-ALA diet showed markedly increased ALA levels (14.9% of total FA content; Supplemental Table II ) compared with tissue from control animals (0.14% of total FA content; Supplemental Table II ). In contrast, EPA and DHA levels did not differ between the 2 groups. Total cholesterol levels were not altered (control: 2.27Ϯ0.17 mmol/L; low ALA: 1.95Ϯ0.21 mmol/L; high ALA: 2.29Ϯ0.30 mmol/L; nϭ8; PϭNS).
Mice on the control diet developed carotid artery thrombosis within a mean occlusion time of 40Ϯ4.2 minutes, whereas mice on a high-ALA diet occluded after 68Ϯ6 minutes (nϭ7; PϽ0.005; Figure 1A ). Initial blood flow did not differ between the 2 groups (nϭ7; PϭNS). Intravenous administration of an inhibitory anti-TF antibody before the onset of photochemical injury reduced the difference in occlusion times between control and high-ALA diets (n Ն7; PϭNS; Figure 1B To analyze differences in thrombus composition, sections from occluded carotid arteries were stained for TF, fibrin, and platelets. Although thrombi were occlusive in both groups, TF staining of in the vascular media was lower in the high ALA group compared with the control group ( Figure 1C ; nϭ4). In contrast, fibrin staining was similar in thrombi from both groups. Analysis of platelet content by immunohistochemistry for CD41 demonstrated a reduced platelet content in thrombi in the ALA-treated group compared with control ( Figure 1D ; nϭ4).
Dietary ALA Inhibits Platelet Aggregation
Thrombin-induced platelet aggregation (Figure 2A Figure 2D ). When aggregation was induced by collagen, a similar inhibition was observed (maximal aggregation: nϭ5, PϽ0.005, Figure 2F ; area under the curve: nϭ5, PϽ0.05, Figure 2G ; lag time: nϭ5, Pϭ0.14, Figure 2H ). Platelet number did not differ significantly between the groups (1062Ϯ46ϫ10 3 
Dietary ALA Inhibits TF Expression and NF-B Activation
TF activity in carotid arteries was markedly decreased in mice fed a high-ALA diet compared with controls (nϭ7; PϽ0.005; Figure 3A) . Inhibition of TF with a specific antibody confirmed that factor Xa generation was TF dependent ( Figure 3B ). This decrease in TF activity was paralleled by an impaired TF mRNA expression in aortic tissue (nϭ7; PϽ0.01; Figure 3C ). In contrast, expression of TF pathway inhibitor mRNA did not differ (⌬⌬Ct: 0.03Ϯ0.04 low ALA group versus 0.03Ϯ0.04 high ALA; nϭ5; PϭNS). NF-B p65 DNA binding affinity was measured in nuclear extracts from aortic tissue. NF-B activity was impaired in mice fed a high-ALA diet compared with controls (OD 490 nm: 0.97Ϯ0.02 [low ALA] versus 0.70Ϯ0.09 [high ALA]; nϭ7; PϽ0.05; Figure 3D ).
ALA Inhibits TF Protein Expression in VSMC
Treatment with ALA (30 mol/L) for 24 hours reduced TF expression in VSMC by 46% (nϭ4; PϽ0.05) compared with control ( Figure 4A ). Real-time polymerase chain reaction analysis confirmed that ALA inhibited TF expression in VSMC at the transcriptional level (nϭ4; PϽ0.005; Figure  4B ). In line with this observation, ALA decreased TF activity in VSMC (nϭ4; PϽ0.001; Figure 4C ). Experiments performed with an inhibitory anti-TF antibody confirmed that factor Xa generation in VSMC was TF dependent ( Figure  4D ). TF expression was affected by neither the n-6 FA ␣-linoleic acid nor the saturated FA stearic acid (nϭ4; PϭNS; data not shown). No cytotoxic effects of ALA, ␣-linoleic acid, or stearic acid in VSMC were observed for any of the concentrations (data not shown).
ALA Inhibits p38 Phosphorylation and NF-B Activity in VSMC
Analysis of the mitogen-activated protein (MAP) kinase phosphorylation demonstrated that treatment of VSMC with ALA for 24 hours resulted in a significant decrease in p38 activation (49Ϯ14% inhibition; nϭ4; PϽ0.05; Figure 5A ). In contrast, activation of c-Jun N terminal kinase and extracellular signalregulated kinase remained unaffected. Blockade of the MAP kinase p38 with SB203580 (10 mol/L) inhibited TF expression in VSMC (nϭ4; PϽ0.01; Figure 5B ). Treatment with ALA (30 mol/L) reduced NF-B p65 DNA binding affinity in nuclear extracts from VSMC (nϭ4; PϽ0.05; Figure 5C ).
ALA Inhibits TNF-␣-Induced TF mRNA Expression via MAP Kinase and Apoptosis Signal-Regulating Kinase 1 in HAEC
HAEC were treated with ALA or vehicle for 1 hour and then stimulated with TNF-␣ (5 ng/mL) for 4 hours. ALA inhibited TNF-␣-induced endothelial TF expression in a concentrationdependent manner with a maximal effect at 30 mol/L (86% inhibition; nϭ5; PϽ0.001 versus TNF-␣ alone; Figure 6A ). In line with this observation, ALA decreased TF activity in HAEC (51% inhibition versus TNF-␣ alone; nϭ4; PϽ0.001; Figure 6B ).
Real-time polymerase chain reaction analysis demonstrated that ALA (30 mol/L) inhibited TNF-␣-induced endothelial TF mRNA expression (nϭ4; PϽ0.001; Figure  6C ). This decrease in TF mRNA was paralleled by an impaired activation of the MAP kinases c-Jun N-terminal kinase, p38, and extracellular signal-regulated kinase (28%, 62%, and 55% inhibition versus TNF-␣ alone, respectively; Figure 6D ). Consistent with this pattern of MAP kinase inhibition, ALA impaired activity of the MAP kinase kinase kinase apoptosis signal-regulating kinase 1 (ASK1) (nϭ3; PϽ0.005 versus TNF-␣ alone; Figure 6E ). Figure 6F ). ALA (30 mol/L) blunted TNF-␣-induced IB-␣ degradation (nϭ3; PϽ0.05). This effect was paralleled by reduced DNA 
nϭ4; PϽ0.05;
ALA (30 mol/L) inhibited TNF-␣-induced TF promoter activation in HAEC by 47% (nϭ4; PϽ0.05;
Discussion
Variations of the dietary n-3/n-6 ratio have been reported to affect the susceptibility to thrombosis in atherosclerotic mice. 29 However, it remains unknown whether ALA can exert such an effect and whether it influences thrombosis directly or via other PUFA.
The present study demonstrates that dietary supplementation with ALA for 2 weeks impaired arterial thrombus formation, platelet activation, TF activity, and NF-B activity in mice in vivo. The ALA-rich diet increased tissue levels of ALA, although there was no significant change in tissue levels of the long-chain n-3 FA EPA and DHA. Consistent with these findings, ALA by itself impaired platelet aggregation and TF induction in different human primary cell cultures. This effect occurred at the transcriptional level, involving inhibition of MAP kinase phosphorylation, NF-B activation, and promoter activation.
The ALA concentrations used for experiments in this study are in a clinically relevant range. Indeed, baseline plasma levels of ALA have been reported to range from 17 to 19 mol/L, whereas a daily oral ingestion of 3 g of ALA leads to ALA plasma levels of 32Ϯ17 mol/L and is well tolerated. 15 Dietary supplementation of ALA for 2 weeks was sufficient to markedly increase the ALA levels in the aortic wall, whereas EPA and DHA levels did not differ from the control group. The lack of a measurable conversion to long-chain n-3 FA is in line with previous epidemiological studies demonstrating that dietary ALA poorly correlates with EPA and DHA levels in adipose tissue, erythrocytes, or plasma. 16 Even more important, the in vivo effects of dietary ALA observed in the present study were mimicked by exogenous ALA in both human platelets and vascular cells ex vivo, where hepatic conversion of ALA to EPA and DHA does not occur. Taken together, these experiments indicate that the antithrombotic effects of ALA in vivo did not depend on the conversion of ALA to long-chain n-3 FA and provide strong evidence for a direct biological effect of ALA.
To exclude possible effects of other FA, control experiments were performed with the n-6 FA linoleic acid, as well as the saturated FA stearic acid. Neither of these FA altered TF expression, supporting the interpretation that the biological effects of the high-ALA diet on TF and thrombosis occur because of the increased ALA levels.
Dietary ALA supplementation significantly delayed arterial thrombus formation was triggered by photochemical injury in vivo. Because this effect was paralleled by a reduced platelet activation and a diminished arterial TF activity, ALA impairs thrombus formation by a dual action on both critical events involved in arterial thrombosis following vascular injury. To determine the relative contribution of platelets and TF to thrombus formation, an inhibitory anti-TF antibody was applied. Treatment with this antibody reduced the difference in occlusion times between the 2 groups, suggesting that the inhibitory effect of ALA on TF exerts a major effect on thrombus formation, whereas its effect on platelets contributes to inhibition of thrombosis. These results support previous observations demonstrating that arterial thrombosis is primarily driven by TF derived from the vessel wall in this model. 30, 31 TF is barely expressed under basal conditions in endothelial cells, whereas it is constitutively expressed in VSMC. 32 Immunohistochemical analysis confirmed that TF expression in the arterial tunica media was decreased in carotid arteries derived from the ALA-treated group. Inhibition of TF was confirmed in vivo, because the ALA-rich diet decreased TF expression and NF-B activity in arterial lysates. Consistent with these in vivo observation, treatment of VSMC with ALA for 24 hours decreased basal TF expression. This effect was mediated at the transcriptional level via the MAP kinase p38. Pharmacological inhibition of p38 confirmed the crucial role of p38 activation in constitu- tive TF expression in VSMC. In line with p38 inhibition, as well as with previous data obtained in monocytes and macrophages, ALA also reduced NF-B activity in VSMC. 33, 34 Hence, direct inhibition of TF in VSMC via p38 and NF-B seems to play a major role in ALA's effect on arterial thrombus formation.
To study whether ALA also affects inducible TF expression, additional experiments were performed in cytokine-activated endothelial cells. TNF-␣-induced endothelial TF expression is mediated through activation of MAP kinases leading to activation of transcription factors such as activator protein-1 and early growth response factor-1, whereas the IB kinase pathway promotes NF-B activation. 35, 36 ASK1 is a redox-regulated kinase playing an essential role in stressinduced activation of MAP kinases, thus triggering various cellular processes, including inflammatory responses and TF expression. 32, 37 In endothelial cells, TNF-␣ has been shown to activate ASK1, as well as MAP kinases. 6, 37 Treatment with ALA significantly reduced phosphorylation of the MAP kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase in endothelial cells. Consistent with the inhibition of MAP kinase phosphorylation, ALA also prevented activation of ASK1. Thus, it is likely that ASK1 represents a common upstream target of ALA, disrupting the MAP kinase signaling pathway in endothelial cells.
Immunohistochemical analysis of CD41 (platelet glycoprotein IIb) expression demonstrated that thrombi contained fewer platelets in the ALA-treated group compared with the control group. Platelet aggregation was analyzed using collagen and thrombin as agonists because they play a dominant role in platelet activation following vascular injury. 3 ALA impaired both collagen-and thrombin-induced platelet aggregation, indicating that ALA inhibits glycoprotein VI and Ib-V-IX, as well as protease-activated receptor-mediated platelet activation; hence, ALA does not interfere with activation of a single pathway. Because the MAP kinase p38 plays a crucial role in collagen-induced, as well as thrombininduced, platelet activation and adhesion, the effect of ALA on p38 phosphorylation in isolated platelets was investigated. 38, 39 ALA decreased collagen-and thrombin-induced p38 activation, an effect that may well account for the reduced aggregation observed in ALA-treated platelets. Taken together, these observations may provide an explanation for the remaining difference in occlusion times observed between the 2 groups after treatment with an inhibitory anti-TF antibody.
In summary, this study provides solid evidence for a potent dual antithrombotic effect of an ALA-rich diet by reducing platelet activation and impairing vascular TF expression. These effects were reproduced in a mouse model, as well as in human primary cell cultures, and were not related to an increase in EPA and DHA levels, as confirmed by our data. Hence, this study generates pathophysiological evidence for direct antithrombotic effects of dietary ALA supplementation. Because limited availability or unfavorable geographic conditions restrict access to n-3 FA from marine origin in many countries, plant-derived ALA might therefore represent an attractive cardioprotective alternative. However, keeping in mind previous clinical setbacks with experimentally promising nutritional compounds such as vitamin E, there is a great need for placebo-controlled randomized large-scale clinical trials to confirm the long-term antithrombotic potential of dietary supplemented ALA.
